References:
- Wood, FM, Giles N Stevenson A, Rea S, Fear M. Characterisation of the cell suspension harvested from the dermal epidermal junction using a Recell® kit. Burns 2012; 38 (1):44-51.
- Navarro FA, Stoner ML, Park CS, et al. Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model. J Burn Care Rehabil 2000;21:513–8.
- Navarro FA, Stoner ML, Lee HB, et al. Melanocyte repopulation in full-thickness wounds using a cell spray apparatus. J Burn Care Rehabil 2001;22:41–6.
- Instructions for Use. RECELL® Autologous Cell Harvesting Device.
- Foster K, Bilir P, Kruger E, et al. Cost-effectiveness of RECELL® Autologous Cell Harvesting Device (ACHD) versus STSG for treatment of severe burns in the United States. Presented at the American Burn Association 2018 Annual Meeting, April 2018.
- Kowal S, Kruger E, Bilir P, et al. Cost effectiveness of the use of autologous cell harvesting device compared to standard of care for treatment of severe burns in the United States. Adv Ther. Published online May 7, 2019. doi: 10.1007/s12325-019- 00961-2.
- Carter JE, Carson JS, Hickerson WL, et al. Length of Stay and Costs with Autologous Skin Cell Suspension Versus Split-Thickness Skin Grafts: Burn Care Data from US Centers [published online ahead of print, 2022 Sep 14]. Adv Ther. 2022;10.1007/s12325-022-02306-y. doi:10.1007/s12325-022-02306-y.
- Carson JS, Carter JE, Hickerson WL, et al. Analysis of real-world length of stay data and costs associated with use of autologous skin cell suspension for the treatment of small burns in U.S. centers [published online ahead of print, 2022 Dec 5]. Burns. 2022;S0305- 4179(22)00299-6. doi:10.1016/j. burns.2022.11.007.
IMPORTANT SAFETY INFORMATION
INDICATIONS FOR USE: The RECELL Autologous Cell Harvesting Device is indicated for the treatment of thermal burn wounds and full-thickness skin defects. The RECELL Device is used by an appropriately licensed and trained healthcare professional at the patient’s point of care to prepare autologous Spray-On Skin Cells for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older, or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients and full-thickness skin defects after traumatic avulsion (e.g., degloving) or surgical excision (e.g., necrotizing soft tissue infection) or resection (e.g., skin cancer) in patients 15 years of age and older.
CONTRAINDICATIONS: RECELL is contraindicated for the treatment of wounds clinically diagnosed as infected or with necrotic tissue present in the wound bed. RECELL is contraindicated for: the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann’s) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.
WARNINGS: Autologous use only. Control infections on wounds prior to application of the cell suspension. Excise the necrotic tissues on wound bed prior to application of the cell suspension. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired.
Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.
PRECAUTIONS: RECELL is not intended for use without meshed autograft for treatment of acute full-thickness burn wounds or full-thickness skin defects after traumatic avulsion (e.g., degloving) or surgical excision (e.g., necrotizing soft tissue infection) or resection (e.g., skin cancer). The safety and effectiveness of RECELL without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints >320cm2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulating joints, and
in patients younger than 28 days of age (neonates). The safety and effectiveness of RECELL plus autografting have not been established for application in combination with meshed autografting on full-thickness skin defects after traumatic avulsion (e.g., degloving) or surgical excision (e.g., necrotizing soft tissue infection) or resection (e.g., skin cancer) on the hands and genitalia.
SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL have not been established for treatment of acute thermal partial- thickness burn wounds in pediatric patients younger than 18 years of age. For complete Important Safety Information, refer to Instructions for Use.
INSTRUCTIONS FOR USE: Consult the Instructions for Use prior to using RECELL. The Instructions for Use can be located at www. RECELLsystem.com.
INSTRUCTIONS FOR USE: Consult the Instructions for Use prior to using RECELL. The Instructions for Use can be located at www. RECELLsystem.com.
©2023 AVITA Medical. AVITA Medical®, the AVITA Medical logo, RECELL®, RES®, Spray-On Skin™, and Benefits Beyond Closure™ are trademarks of AVITA Medical. All other trademarks are the properties of their respective owners.
